New National Lacrosse League Ownership

An exceptional opportunity to acquire a leading International Early Childhood Development Company, renowned for its pioneering integration of digital content in early childhood education, with a strong emphasis on social, emotional, and intellectual development. Programs are offered in more than 20 languages and have an impressive presence in more than 30 countries. The Company’s solid track record of meeting demand and creating growth is backed by an extensive franchise/license network. The Company’s proven teaching models produce exceptional results that have garnered high satisfaction ratings among children and parents alike. Independent research validates the superior outcomes achieved through exclusive age-based programs, enabling children to accelerate their learning levels twice as fast as their peers. The foundation of the Company’s success lies in its Licensing and Master Franchise structure. This highly effective framework enables them to meet local needs and rise above competition; adapting to diverse regional markets, and catering to cultural nuances. With plans for further expansion, the Company is poised to strengthen its position as a global leader in education. The Company has taken intellectual property protection seriously, employing robust safeguards to protect its 95 international trademarks, and 49+ copyrights, via a fortified software registration system. Don't miss this rare opportunity to acquire a thriving global Education Company with a proven model, and a commitment to innovation. Seize the chance to make a profound impact on children's lives while unlocking unlimited potential for growth and success. NDA is required 626to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Facilities: No facilities. It is all virtual. Competition: While operating in a fragmented industry with numerous competitors, what truly distinguishes this Company is its dedication to cultivating essential learning skills that can be universally applied across academic subjects, such as mathematics. By combining digital resources, interactive technology, curriculum development, and effective teaching methods, the Company has long been at the forefront of integrating digital content into early childhood learning. The result is consistently achieving remarkable outcomes and staying ahead of any competitor. Growth & Expansion: Numerous avenues for growth and expansion lie ahead, including: 1. Expand presence by appointing Master Franchisees in Latin America, Asia, and Africa. 2. Strengthen market coverage by adding franchisees to existing geographic territories. 3. Boost brand visibility through enhanced social media marketing strategies. 4. Enhance the current digital curriculum in alignment with the newest and most advanced technology platforms. 5. Explore opportunities to directly sell to US Schools, tapping into a mass market segment. 6. Capitalize on the demand for digital content by offering valuable resources to families. By pursuing these strategic initiatives, the Company can harness its potential for exponential growth and secure a prominent position in the industry. Financing: TBD if deal structure and terms are acceptable. Support & Training: To facilitate a seamless transition and ensure continued success, the Seller is committed to providing comprehensive training and is open to the possibility of remaining as an employee, subject to negotiation regarding salary, duration, and terms. Reason for Selling: The Seller believes that now is an opportune time to sell.

Founded in 2011, the Company is a niche consulting and advisory firm serving in cell therapy, gene and gene-modified cell therapies, other regenerative medicines, tissue engineering, and cell-based drug discovery. The company's core focus is to improve cell & gene therapy innovations by providing consulting services for improving business strategy and achieving major regulatory milestones for companies. The Company has created a one-stop shop for all aspects of cell therapy and gene therapy, including quality checks, regulatory meetings, and submissions with the help of leading experts worldwide. The leadership has a unique combination of experience in the academic, biotech industry, government/FDA, and consulting. They serve biotech, pharma companies, consulting services for healthcare providers, subcontracts for other consulting firms, and contracts with government organizations, which enables them to have 6x+ growth in net income from 2019 2021, i.e., $179,000 to $1,095,000 with the help of 110+ customers served over the past six years. The Company's plan is to consummate a transaction with a supportive growth partner in order to accelerate the company's cell and gene therapy market growth by interacting with industry, academia, government, and other international stakeholders in cell & gene therapies and cell-based drug discovery. NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information Facilities: Has headquarters in US contractors operate nationwide / portable / buyer can be located worldwide. Competition: A few competitors in the space are in the field but the Company provides best in class services for its respective niche(s). Growth & Expansion: Continually grow and become more profitable with the help of experts that supports preclinical, clinical, and commercial advisory in the manufacturing, regulatory affairs, Quality/GxP, and M&A arenas. Financing: If the price and deal structure is right. Support & Training: Long term transition, Seller wishes to smooth the transition to maximize success with the Company post-closing and spearhead continued growth. Reason for Selling: Growth.

Our client operates a lean, high-margin B2B lead-generation platform dedicated to the Internet of Things sector. By leveraging a permission-based community of over 60,000 vetted IoT decision-makers and a LinkedIn Group of 20,000+ approved professionals, they deliver turnkey sponsored webinars, white-paper campaigns, and targeted email blasts—providing technology vendors with consistently qualified leads while maintaining minimal overhead through a fully remote, contractor-driven model. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

This established LLC is offering its proprietary organic dough mixture for sale. A trademark is in place. The creator/owner is a lifelong baker and began experiencing health-related gut issues, as millions of people do. In response, she embarked on a research journey and sourced products from everywhere possible to make a perfect 100% clean, plant-based, organic pizza dough. She wanted to provide pesticide-free dough that could last longer in the fridge, that could take the heat without burning to a crisp and could be boiled, fried, baked, and grilled. She created a dough that could be used every day, in a variety of ways, that wouldn't make you sick. In other words, eating clean, organic dough like the Europeans! Thus, the Company was born! Currently offered in over 300 grocery stores, in both frozen and dry mixes, in a variety of flavors, at a very competitive price point. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Detailed Information: organic yeast, no chemicals Facilities: none Not applicable with this book. Competition: Other health food-based dough mixes that typically are not organic and sell at a higher price point. Growth & Expansion: Unlimited room for expansion and growth in brick-and-mortar stores, as well as online sales and wholesale opportunities. Financing: TBD if structure and terms are acceptable. Royalties are of interest. Support & Training: To ensure a smooth transition and ongoing success the Sellers will work with a buyer as needed for three months, as an on-call consultant, or as negotiated. The seller will introduce the current production/packaging vendor relationship. Reason for Selling: The Seller has developed and runs another business, and is looking to focus her efforts there.

Our client is offering a next generation, patented medical device for the treatment of internal hemorrhoids. The procedure is painless, non-invasive, requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor's office, a surgery center, an endo suite, or a hospital. Our client's product is a small, disposable, medical device that eliminates hemorrhoids. A physician uses this device by deploying a tiny rubber band on the base of the hemorrhoid. This procedure is known as rubber band ligation, and it is the #1 recommended treatment for internal hemorrhoids by the American College of Gastroenterology. Patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. The device is currently manufactured in the USA through an FDA approved, ISO 13485 contract manufacturer, who specializes in medical devices. The device is sold directly to physicians of different specialties, including gastroenterologists, colorectal surgeons, GYNs, urologists and primary care physicians. The biggest targeted audience are gastroenterologists. NDA is required to secure comprehensive Confidential Information Memorandum. Growth and epansion: Nearly half of adults over the age of 50 will develop symptomatic hemorrhoids. In the U.S. alone, an estimated 60,000,000 people have experienced hemorrhoid symptom(s) at some point in their lives. Annually, over 20,000,000 people in the U.S. use an over-the-counter hemorrhoid treatment and 75% report a reoccurrence. These patients no longer need to use ineffective creams or receive painful, invasive surgery. Our client's device offers a permanent solution for their hemorrhoids. Financing is if the price and deal structure is right, and support and training is provided as required. Facilities are Outlined in CIM. Reason for selling is that the owners wish to move on to other projects.

Confidential Information Memorandum (CIM) available upon receipt of our short online NDA. * It is estimated that the marketplace for connected cars and automobile data is will reach $400BN by 2030. * There are currently ~280MM registered automobiles in the US today with ~65MM of them being connected cars * The Company has created a process that while working with 3rd party Companies in the space and simultaneously creating a near proprietary technology is able to harness processes related to car data, thereby creating an opportunity for Companies looking to enter the aftermarket space for consumers and/or enterprises already in the automobile space, * Ideally this would be an add-on solution for any Company that is in the fleet-auto space, or looking to create an expansive and/or sweeping platform for the Consumer space NDA is required to secure comprehensive Confidential Information Memorandum (CIM). Detailed Information: Facilities: Home Based Competition: Few if any Growth & Expansion: Ample Financing: Depending on offer and structure may be acceptable minimal if any Support & Training: As needed. Reason for Selling: Existing opportunities

The Company has proprietary technology that addresses a leading cause of maternal death (76,000) and fetal death (500,000) annually worldwide. 8% of pregnancies in the US and 14% worldwide have diagnoses that would be vastly improved by worldwide commercialization of the Company's proprietary device. A very low risk procedure that both provides quality of life improvement for the mother & baby and lowers health care costs is a win/win/win for all involved. Existing collaborations with major manufacturers coupled with a current expedited approval process with the FDA presents a tremendous opportunity for individuals or private equity groups seeking a transformative investment into a feel-good biotech story with exceptional legs and a vast runway with nearly unlimited upside. Able to work with groups/individuals in tranches of $500k to $1M to advance into the pilot clinical study, $2-$3MM for the pivotal clinical study towards market approval in the US. They will seek direct sales with partnered hospitals, licensing / partnership deals could utlimately yield the balance of funding to fully deploy a commercial version of the technology. NDA is required for comprehensive Confidential Information Memorandum (CIM) crafted by us. Detailed Information Competition: No current option available besides bed rest. Growth & Expansion: Huge market potential. Support & Training: Full team included. Reason for Selling: Seeking supportive capital partners to take to the next level(s). .

Our client is an exploding, music talent agency--yearly revenue has increased since inception, at a percentage rate year over year of approximately 600%. Our client is a 'positive hustle and hard work ethic' music talent business built on the sheer effort of bringing music artists to the performance stage. Built from the ground up, the business foundation has been developing emerging performance talent while using well-known artists to kick in larger revenue when possible. A great source of success has come from acquiring visas for in-demand international artists and bringing them to the US marketplace. Our client brings the following: - 80+ acts signed to exclusive contracts (1-to-2-year terms) - Robust artist scouting protocol signing on average 3 acts a week - Can be staffed with agents anywhere in the world - Access to the nation's largest contact book of venues, talent buyers, and promoters - Non-exclusive booking rights for Snoop Dogg, Ice Cube, OT Genasis, Xzibit, Warren G, Bizzy Bone, B.o.B, and Bone Thugs N Harmony - Over 1,000 performances booked in half of a calendar year (2022) - Artists in several genres are actively leaving their current booking agencies in favor of coming onto our client's roster. Our client has been awarded positive recognition by a large majority of its artists as well as publications like MoneyGeek, DMC World, Pollstar, Gigwell, and Shoutout Atlanta. The Company's key paradigm is to find and monetize talent. Our client's team is constantly scouting new talent locally and internationally and bringing them to the marketplace. Our client consults on all aspects of artist growth from graphic design and social media strategy to music guidance and consulting. Urgency drives the foundations and operations of Our client's enterprise. This has proven to be a successful strategy, as month over month, our client is showing exceptional growth: in 2022 up to July, the Company is averaging $86,500 per month in gross revenue. NDA is required to secure a comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners. Growth/Expansion: In CIM. Financing: Seller does not wish to finance. Support & Training: Provided at no charge to enable a smooth transition. Reason for Selling: other projects.